---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-028203"
form_type: "8-K"
ticker: "SEER"
cik: "0001726445"
company_name: "Seer, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:21:32.516121+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Seer Q2 revenue $4M (+11% YoY); slashes FY2023 guidance to $16-18M from $23-25M

## Summary
- Net loss widened to $23.4M from $22.8M YoY; operating expenses rose 21% to $30.2M.
- Product-related revenue $3.0M including $1.4M related party; service revenue $467K; grant $538K.
- Cash, equivalents and investments at $396M as of June 30, 2023.
- Launched Proteograph XT Assay Kit and STAC service; expanded Thermo Fisher collaboration.
- Guidance cut: now expects FY2023 revenue $16-18M (prior $23-25M), 10% growth at midpoint.

## SEC filing metadata
- accession: 0001628280-23-028203
- form_type: 8-K
- ticker: SEER
- cik: 0001726445
- company_name: Seer, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726445/000162828023028203/0001628280-23-028203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726445/000162828023028203/seer-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-028203
- JSON: https://secwatch.observer/filing/0001628280-23-028203.json
- Plain text: https://secwatch.observer/filing/0001628280-23-028203.txt

## Key facts
- Earnings Releases
  Seer, Inc. reported the second quarter ended June 30, 2023 results: revenue $4.0 million. Guidance lowered.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $4.0 million
  - Guidance: lowered
  - Result: reported results
  source text: commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Achieved revenue of $4.0 million for the second quarter of 2023, an increase of 11% over the prior year period • Launched the Proteograph XT Assay Kit, enabling rapid proteomics across a range of sample types
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726445/000162828023028203/0001628280-23-028203-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.